Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Frequently asked questions
What sector does Cytokinetics, Incorporated (CYTK) operate in?
Cytokinetics, Incorporated belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cytokinetics, Incorporated (CYTK) current stock price?
As of the latest data, Cytokinetics, Incorporated stock price is $73.45, with a previous close of $75.64. Cytokinetics, Incorporated lost -$2.19 in the last trading session, representing a -2.9% loss.
What is Cytokinetics, Incorporated (CYTK) current market capitalization?
Cytokinetics, Incorporated market cap is approximately 9.97 billion.
What is Cytokinetics, Incorporated (CYTK) Earnings Per Share (EPS)?
The trailing EPS is -$6.44, and the forward EPS is -$4.64.
What is Cytokinetics, Incorporated (CYTK) EBITDA?
Cytokinetics, Incorporated EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -191.75 million.
Does Cytokinetics, Incorporated (CYTK) pay dividends?
No. Cytokinetics, Incorporated does not pay a dividend.
How did Cytokinetics, Incorporated (CYTK) perform in its most recent earnings report?
In the last report (June 30, 2026), Cytokinetics, Incorporated posted an EPS surprise of 7.98% and a revenue surprise of 82.77%.
What is Cytokinetics, Incorporated (CYTK) beta (volatility) score?
Cytokinetics, Incorporated has a beta of 0.376, indicating lower volatility than the overall market.
